Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Noah Federman, M.D.
Noah Federman, M.D.

Specialty:

Pediatric Hematology/Oncology

General Information:

Gender:
Male
Language(s):
English, Spanish

Affiliation(s):

Assistant Professor, Department of Pediatrics, Hematology/Oncology
Director, Pediatric Bone and Soft Tissue Sarcoma Program
Member, JCCC Cancer Nanotechnology Program Area

Hospital Affiliation(s):

Mattel Children's Hospital at UCLA
Ronald Reagan UCLA Medical Center
Santa Monica-UCLA Medical Center and Orthopaedic Hospital

Education:

Fellowship:
Pediatric Hematology-Oncology, UCLA School of Medicine, 2005 - 2008
Residency:
Pediatrics, UCLA School of Medicine, 2003 - 2005
Internship:
Pediatrics, UCLA School of Medicine, 2002 - 2003
Medical Degree:
MD, Mount Sinai School of Medicine, 2002

Certification(s):

Board Certification(s):
Pediatrics, American Board of Pediatrics, 2005
Pediatric Hematology/Oncology, American Board of Pediatrics, 2009

Contact Information:

Phone:
(310) 825 6708
Email:

Practice Information:

Clinical Interest(s):
Children with bone and soft tissue sarcomas

Scientific Interest(s):

Dr. Noah Federman’s main scientific interest has been in the field of nanotechnology: developing nanoparticles to specifically target sarcomas and deliver cytotoxic chemotherapy. This novel research may lead to new breakthroughs in targeted therapies for cancer. As a member and institutional principle investigator for the Sarcoma Alliance Research Through Collaboration (SARC), Federman leads an experienced pediatric sarcoma clinical research team with an emphasis towards studying promising new agents in children with very aggressive and often fatal metastatic and refractory bone and soft tissue cancers.

Selected Cancer-Related Publications:

Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, Tap WD. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012 Dec 1;118(23):5888-93. Epub 2012 May 30

Anderson JL, Denny CT, Tap WD, Federman N. Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr Res. 2012 Aug;72(2):112-21.

Mitton B, Federman N. Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies. Sarcoma. 2012 Apr 8;2012:428789.

Federman N, Denny CT. Targeting liposomes toward novel pediatric anticancer therapeutics. Pediatr Res. 2010 May;67(5):514-9.

Federman N, Bernthal N, Eilber FC, Tap WD. The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol. 2009 Apr;10(1-2):82-93. Epub 2009 Feb 24